Physical Therapists in Preston, ID Accepting Medicare
5 Physical Therapists found. Showing 1 - 5
 Mountain Integrated Therapy Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 8 S State St, Preston, ID 83263 Phone: 208-604-1375 |
 Mrs. Tifani Waechtler, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 43 North 100 East, Preston, ID 83263 Phone: 208-852-0116 Fax: 208-852-0116 |
 Dr. Leo E Robertson Iii, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 134 S State St, Preston, ID 83263 Phone: 208-852-4122 Fax: 208-852-7187 |
Mr. Douglas Winward, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 43 North 100 East, Preston, ID 83263 Phone: 208-852-0116 Fax: 208-852-0116 |
Preston Physical Therapy Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 10 S 100 W Ste A, Preston, ID 83263 Phone: 208-852-1143 Fax: 208-852-3951 |
News Archive
Negligent, attentive mouse mothers show biological differences
In mice, child neglect is a product of both nature and nurture, according to a new study.
AMP-activated protein kinase essential contributor to brain growth
An enzyme researchers have studied for years because of its potential connections to cancer, diabetes, heart disease, hypertension and stroke, appears to have yet another major role to play: helping create and maintain the brain.
Merck KGaA initiates Phase 3 START2 study of MUC1 antigen-specific cancer immunotherapy tecemotide
Oncothyreon Inc. today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Discovery could lead to new treatment methods for toxoplasmosis
The parasite responsible for toxoplasmosis requires a stress response system that helps it survive the move to infect new cells, Indiana University School of Medicine scientists have reported, a discovery that could lead to new treatments to control the disease.
IQWiG finds no benefit of high-flow therapy for COPD and type 1 respiratory failure
No benefit of high-flow therapy (HFT) can be derived from the available study data for patients with advanced chronic obstructive pulmonary disease (COPD) or chronic type 1 respiratory failure. It therefore remains unclear whether this form of treatment has advantages over long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV).
› Verified 6 days ago
Chiropractors
Physical Therapists
Optometrists
Speech-Language Pathologists